Dr. Kim is a recognized expert in the field of melanoma, and his research has focused
on targeted therapy and immunotherapy. His research has helped early clinical development
of BRAF inhibitors, such as vemurafenib, dabrafenib, MEK inhibitors, and trametinib,
which are now standard of care for patients with BRAF mutated melanoma. His research
has also included the clinical investigation of therapy for other mutations, including
cKIT and NRAS and also antiangiogenic drugs as well as novel immunotherapy, such as
ipilimumab, anti-PD1 antibodies and cancer vaccines. He is also a senior editor for
the journal Melanoma Management�.
Sutter Health Research Enterprise
2100 Webster Street
San Francisco, CA, 94115
(415) 885-8600
ClinicalResearch@sutterhealth.org
Primary Research Interests
Related Clinical Trials
Adjuvant (BMS CA209-76K)
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma
After Complete Resection of Stage IIB/C Melanoma
Investigator: Kevin Kim MD
Status: Active, Recruiting
Adjuvant (CheckMate 914)
A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants
With Localized Renal Cell Carcinoma (CheckMate 914)
Investigator: Kevin Kim MD
Status: Active, Recruiting
Adjuvant (Moderna Keynote 942)
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157
and Pembrolizumab in Patients With High-Risk Melanoma
Investigator: Kevin Kim MD
Status: Active, Recruiting
Adjuvant (Pivot-12) Coming Soon
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab
Versus Nivolumab After Complete Resection of Melanoma in Patients at High R
Investigator: Kevin Kim MD
Brain Metastasis (Array 818-201 Polaris)
A Phase 2 Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose
Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis
Investigator: Kevin Kim MD
Status: Active, Recruiting
Locally Advanced (CheckMate73L)
A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 Non-small Cell
Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
Investigators: Ari Baron M.D., Caroline Behler MD, Kevin Kim MD, Alan Kramer MD, Wei Wang MD
Status: Active, Recruiting
Locally Advanced or Metastatic (Merck 7339-007)
Study of Olaparib in Combination With Pembrolizumab in the Treatment of HRRm and/or
HRD Positive Advanced Cancer
Investigators: Lejla Delic MD, Kevin Kim MD, Wei Wang MD
Status: Active, Recruiting
Locally Advanced or Metastatic (Nektar PROPEL)
Study of NKTR-214 in Combination With Pembrolizumab and of NKTR-214 in Combination
With Atezolizumab in Patients With Select Advanced or Metastatic Solid Tumors
Investigators: Kevin Kim MD, Wei Wang MD
Status: Active, Recruiting
Locally Advanced or Metastatic 1st line (Merck 003)
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080)
as First-line Intervention in Adults With Advance Melanom
Investigator: Kevin Kim MD
Status: Active, Recruiting
Metastatic (CPMC19-MEL01)
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous
Recombination (HR) Mutation
Investigator: Kevin Kim MD
Status: Active, Recruiting
Metastatic (Tesaro IIP Kim)
Phase II study of niraparib in patients with advanced melanoma with genetic homologous
recombination (HR) mutation / alteration
Investigator: Kevin Kim MD
Status: Active, Recruiting
Uveal Melanoma (Sirspheres Uveal)
Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases
Investigators: Kevin Kim MD, David Minor M.D.
Status: Active, Recruiting